Zura Bio (ZURA) Price & Analysis

Compare

430 Followers

ZURA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.97 - $5.07

Previous CloseN/A

Volume136.30K

Average Volume (3M)936.29K

Market Cap

$87.86M

Enterprise Value-$37.44M

Total Cash (Recent Filing)$170.57M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.40

Next Earnings

Aug 19, 2025

EPS Estimate

-0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.19

Shares Outstanding61,874,996

10 Day Avg. Volume329,824

30 Day Avg. Volume936,293

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.43

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda0.57

Forecast

1Y Price Target

$3.00

Price Target Upside111.27% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Biological RationaleThere is a strong biological rationale for tibulizumab in treating hidradenitis suppurativa, which adds confidence to its potential success.

Clinical TrialsThe timely execution of the Ph 2 TibuSHIELD trial is seen as an important milestone advancing ZURA’s position in the evolving HS landscape.

Company ProgressThe initiation of the TibuSHIELD trial with the first clinical site activated earlier than expected is encouraging for the company's progress.

Bears Say

Competitive PressureDual IL-17A/F inhibitors have demonstrated impressive efficacy in late-stage trials, raising the bar for efficacy compared to IL-17A-only inhibitors.

Efficacy ChallengesThe ianalumab study did not achieve predefined efficacy thresholds, which was a significant near-term catalyst for Zura Bio Limited.

Skepticism In Drug CombinationSkepticism exists that the fusion of an IL-17A-only inhibitor with a BAFF inhibitor would be advantageous in HS, given the intensifying competition and high benchmark set by IL-17A/F dual inhibitors.

Zura Bio News

Novartis trial has positive read for Zura Bio, says Guggenheim

After Novartis (NVS) announced that both of two Phase 3 trials evaluating ianalumab in adults with active Sjogren’s...

22h ago

NVS

ZURA

Cautious Outlook for Zura Bio Amid Competitive Challenges and Historical Concerns

Zura Bio, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell Kapoor from...

25d ago

ZURA

Zura Bio Appoints New CFO Eric Hyllengren

Zura Bio ( ($ZURA) ) has provided an update. On July 1, 2025, Zura Bio announced the appointment...

1M ago

ZURA

Zura Bio appoints Eric Hyllengren as CFO

Zura Bio (ZURA) appointed Eric Hyllengren as CFO, effective July 7. He will succeed Verender Badial, who will...

1M ago

ZURA

Zura Bio participates in a conference call with Piper Sandler

Conference call with management will be held on June 17 hosted by Piper Sandler. Published first on TheFly...

2M ago

ZURA

Zura Bio Highlights Pipeline Progress at Jefferies Conference

An update from Zura Bio ( ($ZURA) ) is now available. On June 4, 2025, Zura Bio Limited...

2M ago

ZURA

Zura Bio to Present at Jefferies Healthcare Conference

The latest update is out from Zura Bio ( ($ZURA) ). On May 27, 2025, Zura Bio announced...

3M ago

ZURA

Zura Bio Holds Annual General Meeting of Shareholders

Zura Bio ( ($ZURA) ) has issued an announcement. On May 21, 2025, Zura Bio Limited held its...

3M ago

ZURA

Zura Bio’s Strategic Advancements and Promising Clinical Trials Support Buy Rating

Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on ZURA stock, giving a Buy rating on...

3M ago

ZURA

Zura Bio Launches TibuSHIELD Phase 2 Study for HS

Zura Bio ( ($ZURA) ) has shared an announcement. On May 20, 2025, Zura Bio announced the launch...

3M ago

ZURA

Zura Bio launches global Phase 2 TibuSHIELD study evaluating tibulizumab

Zura Bio (ZURA) announced the launch of TibuSHIELD, a global Phase 2 clinical study evaluating tibulizumab in adults...

3M ago

ZURA

Zura Bio price target lowered to $17 from $19 at Oppenheimer

Oppenheimer lowered the firm’s price target on Zura Bio (ZURA) to $17 from $19 and keeps an Outperform...

3M ago

ZURA

Zura Bio Reports Q1 2025 Financial Results

Zura Bio Limited ( ($ZURA) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

ZURA

Cautious Hold Rating for Zura Bio Amid Financial Challenges and Clinical Uncertainties

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Hold rating on Zura Bio (ZURA...

4M ago

ZURA

ZURA FAQ

What was Zura Bio Limited’s price range in the past 12 months?

Zura Bio Limited lowest stock price was $0.97 and its highest was $5.07 in the past 12 months.

What is Zura Bio Limited’s market cap?

Zura Bio Limited’s market cap is $87.86M.

When is Zura Bio Limited’s upcoming earnings report date?

Zura Bio Limited’s upcoming earnings report date is Aug 19, 2025 which is in 7 days.

How were Zura Bio Limited’s earnings last quarter?

Currently, no data Available

Is Zura Bio Limited overvalued?

According to Wall Street analysts Zura Bio Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Zura Bio Limited pay dividends?

Zura Bio Limited does not currently pay dividends.

What is Zura Bio Limited’s EPS estimate?

Zura Bio Limited’s EPS estimate is -0.19.

How many shares outstanding does Zura Bio Limited have?

Zura Bio Limited has 61,874,996 shares outstanding.

What happened to Zura Bio Limited’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Zura Bio Limited?

Currently, no hedge funds are holding shares in ZURA

Zura Bio Stock Smart Score

Underperform

Fundamentals

Return on Equity

-62.34%

Trailing 12-Months

Asset Growth

90.64%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Zura Bio Limited

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

Zura Bio (ZURA) Earnings & Revenues

Currently, no data available

Please return soon. This page is being updated.

Historic Earnings Reports

ZURA Stock 12 Month Forecast

Average Price Target

$3.00

▲(111.27% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","1.5":"$1.5","4.5":"$4.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.5,3,4.5,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.05,1.2,1.35,1.5,1.65,1.8,1.95,2.1,2.25,2.4,2.55,2.7,2.8499999999999996,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.05,1.2,1.35,1.5,1.65,1.8,1.95,2.1,2.25,2.4,2.55,2.7,2.8499999999999996,{"y":3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.05,1.2,1.35,1.5,1.65,1.8,1.95,2.1,2.25,2.4,2.55,2.7,2.8499999999999996,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.85,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.15,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.25,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.76,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >